NDURE
DEAD

Serial Number

79379393

Owner

Elasmogen Ltd

Filing Date

Apr 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

NDURE Trademark

Serial Number: 79379393

NDURE is a trademark filed by Elasmogen Ltd on April 19, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Elasmogen Ltd (6 trademarks)

Liberty Building,

Entity Type: 99

Trademark Details

Filing Date

April 19, 2023

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations; biological preparations for medical purposes; diagnostic preparations and materials; therapeutic preparations and substances; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medical use; DNA and/or antibodies and/or proteins that stimulate cells for medical use; DNA, antibodies and proteins for therapeutic use; diagnostic products and reagents for medical use

Medical and pharmacological research services; scientific and technological services and research and design relating thereto; scientific research for medical purposes; pharmaceutical research and development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology services; conducting clinical trials; biological research, clinical research and medical research; providing information about the results of clinical trials for pharmaceutical products; analytic and diagnostic research and laboratory services in the field of science; development of assays, both for products and analysis, provided for others; laboratory services; research and development of new products for others; research and scientific analysis relating to drug discovery, as well as development thereof for others; scientific advisory services; scientific consultancy; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; management of scientific research projects; issuing of scientific information; advisory services relating to scientific and clinical research; provision of information and consultancy in relation to the aforesaid services

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 20, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 8, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 8, 2025 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Aug 19, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 19, 2024 ABN2
REFUSAL PROCESSED BY IB
Feb 27, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 5, 2024 RFCS
REFUSAL PROCESSED BY MPU
Feb 5, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 19, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jan 18, 2024 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jan 18, 2024 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 18, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jan 17, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 17, 2024 DOCK
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jan 2, 2024 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Nov 11, 2023 CRCV
APPLICATION FILING RECEIPT MAILED
Oct 3, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 28, 2023 REPR